PDCD1 and neoplasm: Anti–PD-L1 and lenalidomide lead to functional remodeling of tumor-associated macrophages from M2- to M1-like phenotypes through downregulation of PD-1 and PD-L1 upon NF-κB and JAK/STAT inhibition.